Treatment of refractory T-cell malignancies using gemcitabine

Sabah Sallah, Jim Wan, Nam P. Nguyen

Research output: Contribution to journalArticle

96 Citations (Scopus)

Abstract

We have treated 10 patients with relapsed or refractory T-cell malignancies using gemcitabine. The drug was administered intravenously over 30 min at a dose of 1200 mg/m2 on d 1, 8 and 15 of each 28-d cycle. The mean age of the patients was 62 years and the mean number of administered cycles was three. Of the 10 patients, two achieved a complete response and four a partial response, for an overall response rate of 60% (95% confidence interval 20-35 %). The toxicity of chemotherapy was mild and manageable in all patients. These encouraging results warrant further investigation of gemcitabine either as a single agent or in combination regimens as early salvage treatment for patients with refractory T-cell haematological neoplasms.

Original languageEnglish (US)
Pages (from-to)185-187
Number of pages3
JournalBritish Journal of Haematology
Volume113
Issue number1
DOIs
StatePublished - 2001

Fingerprint

gemcitabine
T-Lymphocytes
Neoplasms
Therapeutics
Salvage Therapy
Hematologic Neoplasms
Confidence Intervals
Drug Therapy

All Science Journal Classification (ASJC) codes

  • Hematology

Cite this

Treatment of refractory T-cell malignancies using gemcitabine. / Sallah, Sabah; Wan, Jim; Nguyen, Nam P.

In: British Journal of Haematology, Vol. 113, No. 1, 2001, p. 185-187.

Research output: Contribution to journalArticle

Sallah, Sabah ; Wan, Jim ; Nguyen, Nam P. / Treatment of refractory T-cell malignancies using gemcitabine. In: British Journal of Haematology. 2001 ; Vol. 113, No. 1. pp. 185-187.
@article{49f9da7550034c2eba771997480167d7,
title = "Treatment of refractory T-cell malignancies using gemcitabine",
abstract = "We have treated 10 patients with relapsed or refractory T-cell malignancies using gemcitabine. The drug was administered intravenously over 30 min at a dose of 1200 mg/m2 on d 1, 8 and 15 of each 28-d cycle. The mean age of the patients was 62 years and the mean number of administered cycles was three. Of the 10 patients, two achieved a complete response and four a partial response, for an overall response rate of 60{\%} (95{\%} confidence interval 20-35 {\%}). The toxicity of chemotherapy was mild and manageable in all patients. These encouraging results warrant further investigation of gemcitabine either as a single agent or in combination regimens as early salvage treatment for patients with refractory T-cell haematological neoplasms.",
author = "Sabah Sallah and Jim Wan and Nguyen, {Nam P.}",
year = "2001",
doi = "10.1046/j.1365-2141.2001.02743.x",
language = "English (US)",
volume = "113",
pages = "185--187",
journal = "British Journal of Haematology",
issn = "0007-1048",
publisher = "Wiley-Blackwell",
number = "1",

}

TY - JOUR

T1 - Treatment of refractory T-cell malignancies using gemcitabine

AU - Sallah, Sabah

AU - Wan, Jim

AU - Nguyen, Nam P.

PY - 2001

Y1 - 2001

N2 - We have treated 10 patients with relapsed or refractory T-cell malignancies using gemcitabine. The drug was administered intravenously over 30 min at a dose of 1200 mg/m2 on d 1, 8 and 15 of each 28-d cycle. The mean age of the patients was 62 years and the mean number of administered cycles was three. Of the 10 patients, two achieved a complete response and four a partial response, for an overall response rate of 60% (95% confidence interval 20-35 %). The toxicity of chemotherapy was mild and manageable in all patients. These encouraging results warrant further investigation of gemcitabine either as a single agent or in combination regimens as early salvage treatment for patients with refractory T-cell haematological neoplasms.

AB - We have treated 10 patients with relapsed or refractory T-cell malignancies using gemcitabine. The drug was administered intravenously over 30 min at a dose of 1200 mg/m2 on d 1, 8 and 15 of each 28-d cycle. The mean age of the patients was 62 years and the mean number of administered cycles was three. Of the 10 patients, two achieved a complete response and four a partial response, for an overall response rate of 60% (95% confidence interval 20-35 %). The toxicity of chemotherapy was mild and manageable in all patients. These encouraging results warrant further investigation of gemcitabine either as a single agent or in combination regimens as early salvage treatment for patients with refractory T-cell haematological neoplasms.

UR - http://www.scopus.com/inward/record.url?scp=0035014189&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0035014189&partnerID=8YFLogxK

U2 - 10.1046/j.1365-2141.2001.02743.x

DO - 10.1046/j.1365-2141.2001.02743.x

M3 - Article

VL - 113

SP - 185

EP - 187

JO - British Journal of Haematology

JF - British Journal of Haematology

SN - 0007-1048

IS - 1

ER -